Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Hu, Zheng, Pan, Xiao-Fen, Wu, Fu-Qun, Ma, Li-Yuan, Liu, Da-Peng, Liu, Ying, Feng, Ting-Ting, Meng, Fan-Yi, Liu, Xiao-Li, Jiang, Qian-Li, Chen, Xiao-Qin, Liu, Jing-Lei, Liu, Ping, Chen, Zhu, Chen, Sai-Juan, Zhou, Guang-Biao
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science 2009
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://ncbi.nlm.nih.gov/pubmed/19606213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006257
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker